Treatment decisions for people with non-radiographic axial spondyloarthritis (nr-axSpA) should not be based on a single test for elevated levels of C-reactive protein (CRP), European clinicians say. Fluctuations are common in CRP results and tests should be repeated after four weeks if they are to be used as a marker of inflammation when determining eligibility ...
Repeat CRP tests advised for nr-axSpA treatment decisions
By Michael Woodhead
18 Sep 2018